)
)
Tarsus Pharmaceuticals Investor Relations Material
Latest events
Investor Update
Tarsus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Tarsus Pharmaceuticals Inc
Access all reports
Tarsus Pharmaceuticals Inc. is a biopharmaceutical company primarily engaged in the development and commercialization of novel therapeutic candidates targeted at various ophthalmic conditions. Its leading product candidate, TP-03, is a novel therapy aimed at treating blepharitis caused by the infestation of Demodex mites and is also being developed to address meibomian gland disease. Furthermore, the company is working on TP-04 for the treatment of rosacea and TP-05, an oral tablet intended for the prevention of Lyme disease and community malaria reduction. Tarsus Pharmaceuticals Inc. is headquartered in Irvine, California, and its shares are listed on the Nasdaq.
Key slides for Tarsus Pharmaceuticals Inc
Investor Update
Tarsus Pharmaceuticals Inc
Investor Update
Tarsus Pharmaceuticals Inc
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
TARS
Country
🇺🇸 United States